EGFR and colorectal carcinoma: KRAS/BRAF-mutant CRC cells are thought to exhibit greater malignant potential in association with a greater likelihood of progression, metastasis, and resistance to EGFR-targeted therapies compared with KRAS/BRAF wild-type CRC cells [2,3].